Argonne National Laboratory Press Release
by Jared Sagoff
September 30, 2019
According to the National Cancer Institute, approximately 38 percent of men and women will be diagnosed with cancer at some point in their lives. The current process for drug discovery is slow and sequential, and often involves high failure rates for drug candidates. Can artificial intelligence (AI) be used to transform the existing drug discovery process into a rapid, integrated, and patient-centric model? Scientists at the U.S. Department of Energy’s (DOE) Argonne National Laboratory think so.
To help drive improved patient outcomes, Argonne has recently announced its commitment to become the newest member of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a public-private partnership between national laboratories, academic institutions and private industry — including life science companies…
